Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

▤ Summary

Fate Therapeutics announced restricted stock unit awards for two newly hired non-executive employees. The grants were approved by the company’s Compensation Committee under its inducement equity plan and follow Nasdaq Rule 5635(c)(4). The RSUs cover 67,300 shares of common stock and vest over four years. This update reflects routine hiring compensation activity at a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies.

▦ Linked Companies